Search hospitals > Kansas > El Dorado
Cancer Center of Kansas - El Dorado
Claim this profileEl Dorado, Kansas 67042
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Recurrence
Conducts research for Non-Small Cell Lung Cancer
382 reported clinical trials
2 medical researchers
Summary
Cancer Center of Kansas - El Dorado is a medical facility located in El Dorado, Kansas. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Non-Small Cell Lung Cancer and other specialties. Cancer Center of Kansas - El Dorado is involved with conducting 382 clinical trials across 445 conditions. There are 2 research doctors associated with this hospital, such as Shaker Dakhil, M.D. and Dennis F. Moore.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderER positive
HER2 negative
HER2 positive
Top PIs
Shaker Dakhil, M.D.Cancer Center of Kansas - Wichita5 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
81 reported clinical trials
168 drugs studied
Dennis F. MooreAscension Via Christi Hospitals Wichita3 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
25 reported clinical trials
69 drugs studied
Clinical Trials running at Cancer Center of Kansas - El Dorado
Breast Cancer
Non-Small Cell Lung Cancer
Bladder Carcinoma
Lung Cancer
Bladder Cancer
Renal Cell Carcinoma
Follicular Lymphoma
Cancer
Colorectal Cancer
Squamous Cell Carcinoma
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Support Program
for Breast Cancer
This study is evaluating whether a support program may help breast cancer patients take their medication correctly.
Recruiting2 awards Phase 34 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Cancer Center of Kansas - El Dorado?
Cancer Center of Kansas - El Dorado is a medical facility located in El Dorado, Kansas. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Non-Small Cell Lung Cancer and other specialties. Cancer Center of Kansas - El Dorado is involved with conducting 382 clinical trials across 445 conditions. There are 2 research doctors associated with this hospital, such as Shaker Dakhil, M.D. and Dennis F. Moore.
Where is Cancer Center of Kansas - El Dorado located?
**Cancer Center of Kansas - El Dorado**
- **Address:** 700 West Central, El Dorado, KS 67042 (Located within Susan B. Allen Memorial Hospital)
- **Contact Number:** (316) 320-9650
Who should I call to ask about financial aid or insurance network?
The Cancer Center of Kansas - El Dorado provides financial assistance through Patient Assistance Counselors in the Business Office. For general financial inquiries, contact the KanCare Ombudsman Office at 1-855-643-8180 or KanCare.Ombudsman@ks.gov. Intermountain Healthcare also offers financial assistance based on family size and gross annual household income.
What insurance does Cancer Center of Kansas - El Dorado accept?
The Cancer Center of Kansas - El Dorado accepts the Secure Hospital Indemnity PlanSM (S-HIP) and the Secure 300 Cancer PlanSM (Secure 300) from Blue Cross and Blue Shield of Kansas. These plans offer cash benefits for hospitalization due to illness or injury and for cancer treatment, supplementing existing health insurance. They are available to Kansas residents with Minimum Essential Coverage, including individual policies, job-based coverage, Medicare, Medicaid, CHIP, TRICARE, and more.
What awards or recognition has Cancer Center of Kansas - El Dorado received?
The Cancer Center of Kansas (CCK), located in El Dorado, has been honored as the Favorite Hospital for Cancer Care in Wichita, Kansas, for the years 2016 and 2018. Its research program, initiated in 1983, is acknowledged by the National Cancer Institute (NCI) as a community-based, nationally recognized research program, now part of the NCI Community Oncology Research Program (NCORP).